Holen Sie sich die Stockscreener-App
3.74
1.06%
-0.04
Handel nachbörslich:
3.95
0.21
+5.61%
Cingulate Inc Aktie (CING) Neueste Nachrichten
Cingulate moves closer to ADHD drug submission By Investing.com - Investing.com South Africa
Cingulate Inc’s Strategic Progress and Promising Clinical Results Justify Buy Rating - TipRanks
Cingulate moves closer to ADHD drug submission - Investing.com India
Cingulate Completes Pre-NDA Meeting With FDA To Discuss New Drug Application For Lead ADHD Asset CTX-1301 - MarketScreener
Cingulate completes pre-NDA meeting with FDA on NDA for CTx-1301 - TipRanks
Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301 - GlobeNewswire
Breakthrough ADHD Treatment Clears Critical FDA Hurdle: Once-Daily Drug Shows Promise - Stock Titan
Roth Capital Issues Positive Outlook for Cingulate Earnings - Defense World
Roth Capital Estimates Cingulate’s Q1 Earnings (NASDAQ:CING) - Defense World
Cingulate (CING) to Release Quarterly Earnings on Monday - Defense World
Cingulate Inc. Reports 2024 Financial and Development Milestones - TipRanks
Cingulate Inc. Reports Full Year 2024, Fourth Quarter - GlobeNewswire
Cingulate's ADHD Drug Nears FDA Filing: Key Trial Results and $17.5M Cash Boost - Stock Titan
Cingulate (CING) Expected to Announce Quarterly Earnings on Monday - Defense World
CING: April Pre-NDA Meeting - Yahoo Finance
Cingulate Inc. adjusts executive compensation - MSN
HC Wainwright Reaffirms Buy Rating for Cingulate (NASDAQ:CING) - Defense World
Promising Prospects for Cingulate Inc.: Buy Rating Backed by Positive Phase 3 Results and Market Potential of CTx-1301 - TipRanks
Breakthrough ADHD Treatment Moves Closer to FDA Approval with New Data - Streetwise Reports
Cingulate reports phase 3 safety data for CTx-1301 to treat ADHD in children, adolescents - Contemporary Pediatrics
Cingulate reports safety results from final Phase 3 trials for CTx-1301 - TipRanks
Cingulate Inc. Advances Towards FDA Approval for CTx-1301 - TipRanks
Cingulate reports promising phase 3 safety data for ADHD treatment By Investing.com - Investing.com Canada
Cingulate reports promising phase 3 safety data for ADHD treatment - Investing.com
Cingulate Reports Safety Results From Final Phase 3 Trials For Lead ADHD Asset CTX-1301 - Marketscreener.com
Cingulate Reports Safety Results from Final Phase 3 Trials - GlobeNewswire
Could This ADHD Drug Breakthrough End Multiple Daily Dosing? Cingulate's Phase 3 Results Point to Yes - StockTitan
What's Going On With Cingulate Shares Recently? - MSN
Cingulate (NASDAQ:CING) Trading Down 2.1% – Here’s Why - Defense World
Cingulate stock price target raised to $20 at H.C. Wainwright - MSN
Cingulate CEO cleared of charges, retains board confidence - Investing.com India
Cingulate CEO cleared of charges, retains board confidence By Investing.com - Investing.com Australia
Q4 Earnings Forecast for Cingulate Issued By HC Wainwright - Defense World
Cingulate (NASDAQ:CING) Price Target Raised to $20.00 - Defense World
Brokers Issue Forecasts for Cingulate FY2025 Earnings - Defense World
Cingulate stock price target raised to $20 at H.C. Wainwright By Investing.com - Investing.com Nigeria
Meta Platforms To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Public company CEO concludes case alleging aggravated domestic battery - The Business Journals
Cingulate Inc. adjusts executive compensation By Investing.com - Investing.com Australia
Jane Street Group LLC Invests $106,000 in Cingulate Inc. (NASDAQ:CING) - Defense World
Cingulate stock rated Buy by Roth/MKM, anticipates $1.6B sales potential - Investing.com Canada
Cingulate (NASDAQ:CING) Coverage Initiated at Roth Mkm - Defense World
Roth Capital Upgrades Cingulate (NASDAQ:CING) to “Strong-Buy” - Defense World
Roth MKM Initiates Coverage of Cingulate (CING) with Buy Recommendation - MSN
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):